Request Demo

Last update 08 May 2025

IL-23R x CD3

Last update 08 May 2025

Basic Info

Related Targets

IL-23RCD3

Drugs associated with IL-23R x CD3

ND007 (Numab Therapeutics)

Target

CD3 x IL-23R

Mechanism

CD3 stimulants [+1]

Active Org.

Numab Therapeutics AG

Originator Org.

Numab Therapeutics AG

Active Indication

Autoimmune Diseases

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with IL-23R x CD3

100 Translational Medicine associated with IL-23R x CD3

0 Patents (Medical) associated with IL-23R x CD3

Literatures (Medical) associated with IL-23R x CD3

24 Feb 2025·Nicotine and Tobacco Research

The Effects of Combustible Cigarettes and Electronic Nicotine Delivery Systems on Immune Cell-Driven Inflammation and Mucosal Healing in Ulcerative Colitis

Article

Author: Arsenijevic, Aleksandar ; Zdravkovic, Marija ; Djonov, Valentin ; Jakovljevic, Vladimir ; Kastratovic, Nikolina ; Markovic, Vladimir ; Volarevic, Vladislav ; Gmizic, Tijana ; Harrell, Carl Randall ; Volarevic, Ana ; Zdravkovic, Natasa ; Brankovic, Marija

AbstractIntroductionThe effects of combustible cigarettes (CCs) and electronic nicotine delivery systems (ENDS) on immune cell-driven colon inflammation and intestinal healing of patients with ulcerative colitis (UC) are still unknown and, therefore, were examined in this study.Aims and MethodsIntracellular staining and flow cytometry analysis of immune cells isolated from UC patients who used ENDS (UCENDS), CCs (UCCC) and who were nonsmokers (UCAIR) were performed to elucidate cellular mechanisms which were responsible for CCs and ENDS-dependent modulation of immune response during UC progression. Additionally, dextran sulfate sodium (DSS)-colitis was induced in ENDS/CC/air-exposed mice (DSSENDS/ DSSCC/DSSAIR groups) to support clinical findings.ResultsSignificantly increased number of immunosuppressive, IL-10, TGF-β, and IL-35-producing, FoxP3-expressing CD3 + CD4 + T regulatory cells (Tregs) was observed in the blood of UCENDS patients while the reduced presence of inflammatory, TNF-α and IFN-γ-producing, Tbx21-expressing CD3 + CD4 + Th1, IL-4-producing Gata3-expresing Th2 and IL-17, IL-22-producing, RORγT, IL-23R-expressing Th17 cells were noticed in the blood of UCCC patients. Exposure to either CCs or ENDS was associated with enhanced mucosal healing, ameliorated spontaneous recovery, and improved survival of DSS-treated mice. An expansion of immunosuppressive cells (IL-10-producing tolerogenic CD11c + dendritic cells, alternatively activated CD206, Arginase 1-expressing, IL-10-producing F4/80 + macrophages, IL-10-producing FoxP3-expressing Tregs) was noticed in the colons of DSSENDS–treated mice, while reduced number of inflammatory, IL-17- and IL-4-producing T lymphocytes was observed in the colons of DSSCC-compared to DSSAIR-treated mice.ConclusionsDespite different mechanisms of action, both ENDS and CCs attenuated ongoing colon inflammation, enhanced healing, and ameliorated recovery of injured intestines of DSS-treated mice and UC patients.ImplicationsThis is the first study that compared the effects of CCs and ENDS on immune cells of patients suffering from UC, providing new information about molecular and cellular mechanisms which were responsible for ENDS and CCs-dependent modulation of immune cell-driven colon injury and inflammation. Obtained results showed that both ENDS and CCs had the capacity to attenuate detrimental immune response, enhance healing, and ameliorate recovery of injured intestines.

01 Dec 2022·Arthritis & Rheumatology

Characterization of mucosal‐associated invariant T cells in blood of patients with axial spondyloarthritis and in axial entheses of healthy controls: comment on the article by Rosine et al

Letter

Author: Laheurte, Caroline ; Saas, Philippe ; Toussirot, Eric

A polemic in response to Rosine et al is given.The article characterized circulating mucosal-associated invariant T (MAIT) cells in patients with axial spondyloarthritis (SpA).The authors also reported that MAIT cells displayed high IL17A and IL23R gene expression and that they may strongly express IL17F gene after stimulation by anti-CD3 and anti-CD28 antibodies plus IL-7 and/or IL-18.

01 Nov 2022·Arthritis & Rheumatology

Characterization of Blood Mucosal‐Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal‐Associated Invariant T Cells From the Axial Entheses of Non‐Axial Spondyloarthritis Control Patients

Article

Author: Cuthbert, Richard ; Yahia‐Cherbal, Hanane ; Rowe, Hannah ; Bridgewood, Charlie ; Newton, Darren ; Rogge, Lars ; McGonagle, Dennis ; Miceli‐Richard, Corinne ; Aimanianda, Vishukumar ; Watad, Abdulla ; Leloup, Claire ; Koturan, Surya ; Sellam, Jeremie ; Rosine, Nicolas ; Bianchi, Elisabetta ; Berenbaum, Francis ; Dougados, Maxime

ObjectiveThe importance of interleukin‐17A (IL‐17A) in the pathogenesis of axial spondyloarthritis (SpA) has been demonstrated by the success of IL‐17A blockade. However, the nature of the cell populations that produce this important proinflammatory cytokine remains poorly defined. We undertook this study to characterize the major IL‐17A–producing blood cell populations in the peripheral blood of patients with axial SpA, with a focus on mucosal‐associated invariant T (MAIT) cells, a population known to be capable of producing IL‐17.MethodsWe evaluated IL‐17A production from 5 sorted peripheral blood cell populations, namely, MAIT cells, γδ T cells, CD4+ T cells, CD8+ T cells, and neutrophils, before and after stimulation with phorbol myristate acetate, the calcium ionophore A23187, and β‐1,3‐glucan. Expression of IL‐17A transcripts and protein were determined using nCounter and ultra‐sensitive Simoa technology, respectively. MAIT cells from the axial entheses of non‐axial SpA control patients (n = 5) were further characterized using flow cytometric immunophenotyping and quantitative polymerase chain reaction, and the production of IL‐17 was assessed following stimulation.ResultsOn a per‐cell basis, MAIT cells from peripheral blood produced the most IL‐17A compared to CD4+ T cells (P < 0.01), CD8+ T cells (P < 0.0001), and γδ T cells (P < 0.0001). IL‐17A was not produced by neutrophils. Gene expression analysis also revealed significantly higher expression of IL17A and IL23R in MAIT cells. Stimulation of peripheral blood MAIT cells with anti‐CD3/CD28 and IL‐7 and/or IL‐18 induced strong expression of IL17F. MAIT cells were present in the normal, unaffected entheses of control patients who did not have axial SpA and showed elevated AHR, JAK1, STAT4, and TGFB1 transcript expression with inducible IL‐17A protein. IL‐18 protein expression was evident in spinal enthesis digests.ConclusionBoth peripheral blood MAIT cells and resident MAIT cells in normal axial entheses contribute to the production of IL‐17 and may play important roles in the pathogenesis of axial SpA.

News (Medical) associated with IL-23R x CD3

15 Jan 2025

·pmlive.com

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for multiple myeloma. The companies have entered into an option to licence agreement for Simcere Zaiming’s SIM0500, a trispecific antibody currently in phase 1 clinical development in the US and China for patients with relapsed or refractory multiple myeloma. Approximately 24,000 people in the UK are affected by multiple myeloma, a type of haematological malignancy that develops in plasma cells in the bone marrow. The disease accounts for 15% of all blood cancers and, despite available treatments, remains incurable. Developed with Simcere Zaiming’s T-cell engager polyspecific antibody technology platform, SIM0500 is a designed to target GPRC5D, BCMA and CD3, and has already demonstrated strong T cell cytotoxicity against multiple myeloma cells by leveraging a combination of various anti-tumour effects. Under the terms of the agreement, Simcere Zaiming will receive an undisclosed upfront payment and will be eligible for up to $1.055bn in option fees and milestones. The Simcere Pharmaceutical subsidiary will also be in line for tiered royalties on net sales outside the Greater China territory, while AbbVie will be eligible for tiered royalties within the Greater China territory. Mariana Cota Stirner, vice president, therapeutic area head for haematology, AbbVie, said: “We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people living with multiple myeloma.” Simcere Zaiming’s chief executive officer, Renhong Tang, added: “We are excited to partner with AbbVie on this novel drug candidate and look forward to working together to advance the clinical development of SIM0500.” The agreement comes just one month after AbbVie announced that it would be expanding its immunology pipeline by acquiring Nimble Therapeutics for $200m. The deal includes Nimble’s lead asset, an investigational oral peptide IL23R inhibitor currently in preclinical development for psoriasis and inflammatory bowel disease, as well as a pipeline of other oral peptide candidates with potential across several autoimmune diseases. AbbVie also recently revealed that it would be acquiring Aliada Therapeutics and its central nervous system disease drugs for $1.4bn.

Phase 1License out/inAcquisition

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis